Login or sign up
For business

Pharmaengine inc

4.0· 10 reviews
Average ratingGreat
4.0/ 5

Based on 10 reviews

530%
440%
330%
20%
10%
Turtle Truly
Reviews 1

I had a relatively good experience with Pharmaengine inc. The website was easy to navigate, and the prices were fair. The only downside was the customer support, which took longer than expected to respond. Overall, I would recommend this company for their competitive prices.

Melody Kramer
Reviews 1

I had a mixed experience with Pharmaengine inc. Overall, their service was average at best. The website was user-friendly, but the response time was quite slow. The company needs to improve on their communication and customer support. The prices were reasonable, though, and the delivery was on time.

Patrick McInnis
Reviews 1

I recently used the services of a pharmaceutical company and I must say I was quite impressed. The website was easy to navigate and had all the information I needed. The company provided quick and reliable service, and the prices were competitive. I would highly recommend them to others.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Pharmaengine inc

PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 3 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, was approved by both the US FDA and Taiwan FDA in 2015, European Medicines Agency (EMA) in 2016, Korea MFDS and Singapore HAS in 2017. PEP503 (NBTXR3), a nanoparticle working as a radio-enhancer, is in a positive global pivotal trial of soft tissue sarcoma, the other ongoing studies are in Phase I/II trial in head and neck cancerand rectal cancer in Taiwan. PEP06, a new chemical entity (NCE) for cancer treatment, is currently in the pre-clinical stage.